Bottom line
FHCLX vs PRHSX: the short answer
FHCLX (Health Care Portfolio) and PRHSX (T. Rowe Price Health Sciences Fund, Inc.) are both mutual funds.
PRHSX is cheaper at 0.83% vs 0.91% — a difference of $8.00 a year per $10,000 invested.
Over five years, PRHSX returned +4.2% a year vs +4.0% for FHCLX (reporting dates differ).
Updated Nov 19, 2026
FHCLX vs PRHSX side by side
| FHCLX | PRHSX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Fidelity | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.91% | 0.83% |
| Annual cost per $10k | $91 | $83 |
| 10-yr cost on $10k (prospectus) | $1,630 | $1,025 |
| Max front load | — | — |
| 12b-1 fee | 0.25% | — |
| 1-yr return | +14.4% | +17.7% |
| 5-yr return (annualized) | +4.0% | +4.2% |
| 10-yr return (annualized) | +9.0% | +9.1% |
| Best quarter | +22.2% | +23.5% |
| Worst quarter | −15.0% | −15.8% |
| Net assets (fund) | $5.8B | $11.9B |
| Number of holdings | 152 | 279 |
| Portfolio turnover | 69% | 62% |
| Returns as of | Feb 28, 2026 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FHCLX | PRHSX | Difference |
|---|---|---|---|
| 2025 | +14.4% | +17.7% | −3.3% |
| 2024 | +4.9% | +1.8% | +3.1% |
| 2023 | +4.1% | +3.1% | +1.1% |
| 2022 | −12.8% | −12.2% | −0.6% |
| 2021 | +11.5% | +13.3% | −1.8% |
| 2020 | +24.4% | +30.1% | −5.7% |
| 2019 | +31.5% | +29.1% | +2.3% |
| 2018 | +7.4% | +1.2% | +6.2% |
| 2017 | +24.0% | +28.0% | −3.9% |
| 2016 | −10.7% | −10.4% | −0.3% |
Source: Fund prospectus bar charts
Holdings overlap
12 of FHCLX's top 25 holdings also appear in PRHSX's top 25.
| Holding | FHCLX | PRHSX |
|---|---|---|
| ELI LILLY and CO | 8.03% | 14.28% |
| Danaher Corp | 6.89% | 1.43% |
| JOHNSON and JOHNSON | 4.91% | 6.63% |
| Thermo Fisher Scientific Inc | 4.33% | 2.52% |
| Unitedhealth Group Inc | 3.49% | 5.99% |
| Gilead Sciences Inc | 2.21% | 2.82% |
| Abbvie Inc | 2.03% | 5.10% |
| MERCK and CO INC | 1.60% | 4.01% |
| Cvs Health Corp | 1.29% | 0.94% |
| Natera Inc | 1.27% | 1.44% |
| Brightspring Health Services Inc | 1.23% | 0.82% |
| Moderna Inc | 1.18% | 0.83% |
Source: SEC Form N-PORT
FHCLX top 10
- ELI LILLY and CO — 8.03%
- Danaher Corp — 6.89%
- JOHNSON and JOHNSON — 4.91%
- Thermo Fisher Scientific Inc — 4.33%
- Unitedhealth Group Inc — 3.49%
- Alnylam Pharmaceuticals Inc — 2.40%
- Gilead Sciences Inc — 2.21%
- Boston Scientific Corp — 2.17%
- Ascendis Pharma A/s — 2.17%
- Fidelity Revere Street Trust — 2.17%
PRHSX top 10
- Eli Lilly & Co — 14.28%
- Johnson & Johnson — 6.63%
- Unitedhealth Group Inc — 5.99%
- Abbvie Inc — 5.10%
- Merck & Co. Inc. — 4.01%
- Gilead Sciences Inc — 2.82%
- Thermo Fisher Scientific Inc — 2.52%
- Vertex Pharmaceuticals Inc — 2.28%
- Bristol-myers Squibb Co — 2.11%
- Abbott Laboratories — 1.89%
FAQ
What is the difference between FHCLX and PRHSX?
Which is cheaper, FHCLX or PRHSX?
Should I own both FHCLX and PRHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.